Revance Therapeutics, Inc. (RVNC) Financials
Stock symbol RVNC is outdated, potentially delisted? Maybe it is available on other exchange?
RVNC Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2024 | 461.6 million | 624.6 million |
| June 30, 2024 | 494.8 million | 624.5 million |
| March 31, 2024 | 508.1 million | 606.8 million |
| Dec. 31, 2023 | 478.5 million | 630.1 million |
RVNC Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2024 | -41.2 million | 4.6 million |
| June 30, 2024 | -41.6 million | 5.8 million |
| March 31, 2024 | -67.7 million | 9.0 million |
| Dec. 31, 2023 | -44.5 million | 8.8 million |
RVNC Net Income
No data available :(
RVNC Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2024 | 184.1 million | 456.1 million | - |
| June 30, 2024 | 232.5 million | 460.0 million | 61.1 million |
| March 31, 2024 | 277.6 million | 463.7 million | 45.9 million |
| Dec. 31, 2023 | 254.5 million | 467.6 million | 49.3 million |
RVNC Shares Outstanding
RVNC Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2024 | 61000 | 11.4 million | 62.6 million | - |
| June 30, 2024 | 470000 | 15.5 million | 65.4 million | 123000 |
| March 31, 2024 | 1.7 million | 13.6 million | 67.5 million | - |
| Dec. 31, 2023 | 1.8 million | 19.7 million | 84.3 million | 253.4 million |
RVNC Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2024 | 58.8 million | 17.6 million |
| June 30, 2024 | 65.4 million | 19.1 million |
| March 31, 2024 | 51.9 million | 16.9 million |
| Dec. 31, 2023 | 69.8 million | 18.9 million |
RVNC Revenue by Segment
Graph available only for paid members. Upgrade to see it.
RVNC
Price: $3.65
52 week price:
Earnings Per Share: -3.34 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 728800
Ebitda: -30.2 millionMarket Capitalization: 381.0 million